ORIGINAL ARTICLE

Aberrant expression of Np73 in benign and malignant tumours of the prostate: correlation with Gleason score

M Guan and Y Chen

Centre of Laboratory Medicine, Hua Shan Hospital, Fudan University, Shanghai, 200040, PR China

Correspondence to:
Correspondence to:
Dr M Guan
Centre of Laboratory Medicine, Hua Shan Hospital, Fudan University, Shanghai, 200040, PR China; ming_guan88{at}yahoo.com

Background: The p73 gene is a p53 homologue that induces apoptosis and inhibits cell proliferation. N-terminal truncated isoforms of p73 (Np73) act as dominant-negative inhibitors of wild-type p53 and TAp73 and result in tumour growth in nude mice.

Aims: To detect Np73 expression in 24 benign prostatic hyperplasia samples, 33 prostate carcinomas, and five normal samples and to evaluate the relation between Np73, TAp73 concentrations, and the clinicopathological characteristics of patients with prostate cancer.

Methods: TAp73 was determined by real time polymerase chain reaction (PCR); Np73 and N’p73 were assessed using reverse transcription PCR. western blotting was used to analyse protein expression. p53 mutation was determined by immunohistochemistry.

Results: A significant increase of Np73 was seen in 20 of 33 carcinomas and 17 of 24 benign prostate hyperplasia tissues, but in none of the normal samples. None of the specimens expressed N’p73. No significant relation was found between TAp73 expression and clinical parameters. The incidence of positive expression of Np73 correlated with the Gleason score in prostate carcinomas. Cancer samples with wild-type p53 had significantly higher expression of Np73 than p53 mutant cancers.

Conclusion: These data suggest a potential role for Np73 in prostate cancer progression.

Abbreviations: N, N truncated; BPH, benign prostate hyperplasia; Ct, cycle threshold; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PBS, phosphate buffered saline; PCa, prostate carcinoma; PCR, polymerase chain reaction; PSA, prostate specific antigen; RT, reverse transcriptase

Keywords: Np73; p73; p53; prostate cancer

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Malaguarnera, R., Vella, V., Pandini, G., Sanfilippo, M., Pezzino, V., Vigneri, R., Frasca, F. (2008). TAp73{alpha} Increases p53 Tumor Suppressor Activity in Thyroid Cancer Cells via the Inhibition of Mdm2-Mediated Degradation. Mol Cancer Res 6: 64-77 [Abstract] [Full Text]  
• Tannapfel, A., John, K., Mise, N., Schmidt, A., Buhlmann, S., Ibrahim, S. M., Putzer, B. M. (2008). Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor DNp73. Carcinogenesis 29: 211-218 [Abstract] [Full Text]  
• Azare, J., Leslie, K., Al-Ahmadie, H., Gerald, W., Weinreb, P. H., Violette, S. M., Bromberg, J. (2007). Constitutively Activated Stat3 Induces Tumorigenesis and Enhances Cell Motility of Prostate Epithelial Cells through Integrin {beta}6. Mol. Cell. Biol. 27: 4444-4453 [Abstract] [Full Text]  
• Malaguarnera, R, Vella, V, Vigneri, R, Frasca, F (2007). p53 family proteins in thyroid cancer. Endocr Relat Cancer 14: 43-60 [Abstract] [Full Text]  
• Watson, I. R., Blanch, A., Lin, D. C. C., Ohh, M., Irwin, M. S. (2006). Mdm2-mediated NEDD8 Modification of TAp73 Regulates Its Transactivation Function. J. Biol. Chem. 281: 34096-34103 [Abstract] [Full Text]